

Translation

Notice: This document is an excerpt translation of the original Japanese document and is for reference purposes only. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

May 14, 2025

FOR IMMEDIATE RELEASE

Company name: H.U. Group Holdings, Inc.
Representative: Shigekazu Takeuchi, Chairman and President
Securities code: 4544 Prime Market, Tokyo Stock Exchange
Contact: Naoki Kitamura, Managing Executive Officer and CFO
Telephone No.: +81-3-6279-0926

**Notice Concerning Revisions to Full-year Consolidated Earnings Forecasts for the Fiscal Year
Ending March 31, 2025**

H.U. Group Holdings, Inc. hereby announces revisions to its full-year consolidated earnings forecasts for the fiscal year ending March 31, 2025, previously announced on February 7, 2025, based on recent performance trends. Details are as follows.

1. Revisions to full-year consolidated earnings forecast for the fiscal year ending March 31, 2025 (April 1, 2024 - March 31, 2025)

	Net sales (Million yen)	Operating profit (Million yen)	Ordinary profit (Million yen)	Profit attributable to owners of parent (Million yen)	Earnings per share (Yen)	(Reference) EBITDA* (Million yen)
Previous forecast (A) (Announced on February 7, 2025)	241,000	4,500	6,000	3,000	52.80	25,500
Revised forecast (B)	243,000	2,600	4,700	2,700	47.52	23,300
Change (B - A)	2,000	-1,900	-1,300	-300	—	-2,200
Change (%)	0.8	-42.2	-21.7	-10.0	—	-8.6
(Reference) Results for the fiscal year ended March 31, 2024	236,950	-4,043	-7,241	-7,553	-132.77	16,280

* EBITDA = Operating profit + Depreciation + Amortization of goodwill

2. Reasons for revisions

Net sales are expected to be broadly in line with the previous forecast. However, in the fourth quarter, fixed cost reduction initiatives in the LTS business progressed less than expected and base business growth in the IVD business also underperformed the previous expectations. In addition, a portion of the profits initially

expected as operating profit is now expected to be recorded as non-operating profit.

As a result, operating profit is expected to be approximately ¥1.9 billion below the earnings forecast announced on February 7, 2025. Ordinary profit is expected to fall short of the forecast, reflecting the lower operating profit and foreign exchange impacts, despite an improvement in equity-method investment losses, driven by accounting gains related to partial capital repayment (\$25 million) and a reduction in common stock equity, as noted in the April 9, 2025 announcement titled “Baylor Genetics Raises \$50 Million in Funding”. Profit attributable to owners of parent is similarly expected to fall short of initial expectations.

The year-end dividend forecast remains unchanged at ¥63 per share.

The above earnings forecast is based on information available as of the date of this announcement and may differ from actual results due to future factors.

End